This episode of This Week in Microbiology (TWiM) delves into two groundbreaking studies in microbial science. The first explores the fascinating duality of Vibrio fischeri, a bacterium famously known for its mutualistic bioluminescent relationship with the Hawaiian bobtail squid. Research reveals that this mutualist can turn lethal when exposed to non-symbiotic hosts like zebrafish embryos and brine shrimp, utilizing its Type VI secretion system in a nuanced and host/strain-specific manner, challenging traditional definitions of bacterial mutualism and pathogenesis. The second study presents a significant advancement in tuberculosis vaccine development: a genetically engineered Mycobacterium bovis BCG strain with a tetracycline-inducible "kill switch." This innovative live-attenuated vaccine demonstrates improved safety by allowing for programmed bacterial lysis, while still eliciting robust and protective T-cell mediated immune responses in both immunocompromised mice and non-human primates, with an exceptionally low mutation rate for escape mutants.
Exploring Microbial Duality and Vaccine Innovation:
0:24 Podcast Introduction: Hosts Vincent Racaniello, Michelle Swanson, Michael Schmidt, and Petra Levin introduce TWiM episode 333, covering two papers on microbial mutualism and TB vaccine development.
0:41 Host Personal Anecdotes: The hosts share personal anecdotes, including Petra Levin's experience with a tornado hitting her house and Michael Schmidt's reflections on natural disasters, leading into a call for support for Microbe.tv.
4:04 Support Microbe.tv: The hosts encourage listeners to support their non-profit science podcasts via microbe.tv/contribute, highlighting their commitment to providing factual, ad-free information.
4:58 Paper 1: When a Mutualist Becomes Lethal: Michael Schmidt introduces a paper from mBio on Vibrio fischeri, challenging perceptions of bacterial mutualism and pathogenesis.
6:03Vibrio fischeri Mutualism: Classically known for its bioluminescent symbiosis with the Hawaiian bobtail squid, providing camouflage for the squid.
7:46 The Paradox of Virulence Factors: Despite possessing "weapons" like secretion systems, V. fischeri typically doesn't harm its symbiotic host.
8:04 Mutualist Turns Pathogen: Researchers exposed V. fischeri to non-symbiotic hosts (zebrafish embryos, brine shrimp) and observed dose-dependent mortality.
12:46 Direct Interaction Required: Lethality was dependent on live V. fischeri cells and direct association with host tissues, not secreted toxins.
13:12 Host Damage: Surviving zebrafish embryos exhibited significant developmental defects, including stunted growth, necrotic tissue, and abnormal tail curvatures, indicating a harmful interaction.
15:56 Mechanism - Type VI Secretion System (T6SS): The Type VI secretion system from V. fischeri's first chromosome was identified as essential for this pathogenic behavior in non-symbiotic hosts, acting as a "molecular harpoon" to inject effectors.
18:58 Nuanced Host/Strain Specificity: The role of T6SS in lethality was found to be both host- and strain-specific, complicating a simple one-to-one relationship.
20:51 Implications for Pathogenesis: The study reveals V. fischeri has dual capabilities (beneficial and pathogenic), highlighting the nuanced nature of microbial pathogenesis.
21:23 Broader Context: Discussion on how microbes can cause disease in "wrong hosts" (like viruses), and the concept of mutualism and virulence as two sides of the same coin.
26:23 Paper 2: Engineering a Kill Switch for Tuberculosis Vaccine: Michelle Swanson introduces a paper from Nature Microbiology on a safer BCG vaccine for Mycobacterium tuberculosis (MTB).
27:16 Tuberculosis Global Impact: MTB is the number one cause of infectious disease globally, causing over 10 million cases annually. A third of the world's population harbors latent TB.
29:11 Current BCG Vaccine: Developed over 100 years ago from M. bovis, BCG is a live-attenuated vaccine used in newborns worldwide, but carries risks for immunocompromised individuals and infants (e.g., meningitis), and isn't used in the US for general vaccination due to low prevalence and interference with PPD tests. It is used in the US for bladder cancer treatment.
30:46 Motivation for a Safer Vaccine: The inherent risks of a live-attenuated vaccine, particularly for vulnerable populations, necessitate a safer alternative.
31:08 Challenge for New Vaccines: Inactivated or subunit vaccines primarily stimulate antibodies, which are ineffective against MTB replicating inside white blood cells; T-cell mediated immunity is crucial.
31:46 The "Kill Switch" Design: Researchers engineered a BCG strain (BCG TET off DL) to carry a kill switch, using phage-encoded lysins expressed under a tetracycline-inducible promoter, allowing scientists to turn off replication at will.
33:14 In Vitro & In Vivo Testing: Demonstrated that tetracycline addition caused a three-log drop in CFU and bacterial lysis in broth. In mice, the strain persisted, but withdrawal of tetracycline led to clearance of the vaccine strain, even in immunocompromised (SKID) mice, confirming safety.
35:26 Robust Immune Response: The kill switch strain elicited similar populations of CD4 and CD8 T-cells in mice as the classic BCG, indicating strong immunogenicity.
36:06 Protection in Mice: Vaccinated mice showed a significant reduction of MTB burden in lungs and spleens after exposure to infectious TB, with the engineered strain providing protection, albeit slightly less robust than classic BCG due to shorter exposure time.
37:32 Non-Human Primate Studies: Experiments in macaques confirmed the vaccine's safety and efficacy, showing clearance of the vaccine strain, robust immune responses, and unremarkable tissue histology.
39:44 Protection in Macaques: The BCG TET off DL protected macaques from MTB infection, with 75% of vaccinated animals having sterile tissues compared to 25% with classic BCG.
41:51 Enhanced Immune Response Mechanism: Programmed lysis of BCG generated a larger population of CD4+ T-cells and more interferon-gamma and TNF in the lungs, likely due to the release of mycobacterial cell fragments stimulating host defense.
43:06 Genetic Stability & Safety Margin: The kill switch strain exhibited an incredibly low mutation rate for escape mutants (2 * 10^-9 per cell division), well within safety margins (over three orders of magnitude safer than the "six sigma" engineering standard).
45:07 Patent and Future Outlook: A patent is pending for this BCG strain. A companion paper explored a triple switch kill strain for MTB itself, demonstrating even greater stability.
46:31 Global Collaboration: The researchers are part of a global effort against TB, including the WHO's Stop TB partnership, with numerous vaccine candidates and drugs in clinical trials.
47:33 Delivery Challenges: Discussion on the challenge of IV immunization for broad populations, but acknowledging it as a strong starting point for new vaccine technologies.
48:50 Innovation and Collaboration: The hosts praise the innovative technology and collaborative spirit of the research, highlighting it as a significant step forward for a disease that has been with humanity for a long time.
49:03 First Authors' Contributions: Michelle introduces the three co-first authors: Joshua Wallik (long-term lab member, focused on safety), Alex Smith (passion for vaccine research, valued collaboration), and Honguay Su (focused on latent TB, international collaboration).
54:19 "Mission Impossible" Vaccine: Michael likens the kill switch BCG to a "Mission Impossible" vaccine that will self-destruct after performing its task of inducing immunity.
55:34 TB Prevalence: Reiteration that one-third of the world's population has TB, though incidence is lower in the US due to public health programs.
57:19 Conclusion: The hosts conclude the episode, encouraging listeners to find show notes at microbe.tv/twim and support their work at microbe.tv/contribute.